| scholarly article | Q13442814 |
| P2093 | author name string | Mingxia Wu | |
| Christy W. S. Tong | |||
| Kenneth K. W. To | |||
| William C. S. Cho | |||
| P2860 | cites work | Combination anastrozole and fulvestrant in metastatic breast cancer | Q24595386 |
| Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer | Q26738985 | ||
| Optimal management of hormone receptor positive metastatic breast cancer in 2016 | Q26777683 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Q27853337 | ||
| PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions | Q28071345 | ||
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
| Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer | Q28275492 | ||
| Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies | Q29617680 | ||
| Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer | Q29619481 | ||
| Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer | Q29620676 | ||
| Incidence of breast cancer in the United States: current and future trends. | Q30504517 | ||
| The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer | Q33409083 | ||
| Recent advances of highly selective CDK4/6 inhibitors in breast cancer | Q33602076 | ||
| Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. | Q33925164 | ||
| Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer | Q33968076 | ||
| Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer | Q34022546 | ||
| Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients | Q34083121 | ||
| Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole | Q34789970 | ||
| Triple-negative breast cancer: new perspectives for targeted therapies. | Q35001758 | ||
| Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes | Q35021314 | ||
| A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer | Q35034708 | ||
| HER2 therapy: molecular mechanisms of trastuzumab resistance. | Q35633712 | ||
| Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. | Q35836070 | ||
| Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer | Q35861503 | ||
| A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. | Q55026505 | ||
| A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. | Q55026796 | ||
| Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy. | Q55067446 | ||
| Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 | ||
| Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer | Q57391370 | ||
| IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients | Q58333416 | ||
| Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas | Q73404056 | ||
| Tamoxifen in the treatment of breast cancer | Q77598704 | ||
| FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer | Q83523415 | ||
| Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy | Q87177751 | ||
| TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer | Q36145430 | ||
| Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades | Q36306315 | ||
| Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines | Q36364998 | ||
| Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. | Q36494245 | ||
| Steroid sulfatase: a new target for the endocrine therapy of breast cancer | Q36807131 | ||
| Phase II trial of temsirolimus in patients with metastatic breast cancer | Q36856121 | ||
| Past, present, and future challenges in breast cancer treatment | Q36934273 | ||
| Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a | Q36938662 | ||
| Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer | Q37375251 | ||
| Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. | Q37671599 | ||
| Genomic architecture characterizes tumor progression paths and fate in breast cancer patients | Q37678826 | ||
| A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors | Q37690991 | ||
| The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer | Q37720246 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). | Q37768426 | ||
| Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? | Q37799942 | ||
| Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism | Q37892693 | ||
| MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. | Q38376037 | ||
| A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. | Q38382173 | ||
| Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. | Q38393045 | ||
| Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer. | Q38678738 | ||
| Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order | Q38718012 | ||
| The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer | Q38757501 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| Palbociclib and Letrozole in Advanced Breast Cancer | Q39105459 | ||
| Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells | Q39118034 | ||
| Neoadjuvant Therapy for HER2-positive Breast Cancer | Q39121695 | ||
| Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation | Q39348799 | ||
| Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study | Q39693553 | ||
| Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer. | Q39920942 | ||
| Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind | Q39944735 | ||
| Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor | Q41189355 | ||
| Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. | Q41655720 | ||
| PARP inhibitors: the race is on. | Q42356655 | ||
| Antibodies to watch in 2013: Mid-year update | Q42724515 | ||
| Heterogeneity in breast cancer | Q42942060 | ||
| Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. | Q43755864 | ||
| Combination endocrine therapy in the management of breast cancer | Q43822555 | ||
| Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer | Q44073626 | ||
| Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, mult | Q44699072 | ||
| RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer | Q44963911 | ||
| Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. | Q45044547 | ||
| Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. | Q45956350 | ||
| EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer | Q46535209 | ||
| Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer | Q46771645 | ||
| Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer | Q47126394 | ||
| Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. | Q47185834 | ||
| PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. | Q47741271 | ||
| Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study | Q50089515 | ||
| First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. | Q51170722 | ||
| Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. | Q53158182 | ||
| Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. | Q54300242 | ||
| Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. | Q54478541 | ||
| A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer. | Q54558859 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cancer research | Q3421914 |
| P304 | page(s) | 227 | |
| P577 | publication date | 2018-06-14 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Recent Advances in the Treatment of Breast Cancer. | |
| P478 | volume | 8 |
| Q99725931 | 6-Methoxymellein Isolated from Carrot (Daucus carota L.) Targets Breast Cancer Stem Cells by Regulating NF-κB Signaling |
| Q64948510 | A Splice Site Variant of CDK12 and Breast Cancer in Three Eurasian Populations. |
| Q91642406 | A three layered histone epigenetics in breast cancer metastasis |
| Q91611020 | Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer |
| Q92434900 | CpG promoter hypo-methylation and up-regulation of microRNA-190b in hormone receptor-positive breast cancer |
| Q98771281 | Cytochrome P450 2U1 Is a Novel Independent Prognostic Biomarker in Breast Cancer Patients |
| Q92604087 | Development of CAPER peptides for the treatment of triple negative breast cancer |
| Q95577346 | Drug repurposing for breast cancer therapy: Old weapon for new battle |
| Q93012423 | ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer |
| Q61807139 | EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival |
| Q91935115 | Epidemiology and Challenges of Managing Breast Cancer in Keffi, North-Central Nigeria: A Preliminary Report |
| Q90724533 | Evidences from a Systematic Review and Meta-Analysis Unveil the Role of MiRNA Polymorphisms in the Predisposition to Female Neoplasms |
| Q61798865 | Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells |
| Q90628313 | Gap Junctions and Breast Cancer Dormancy |
| Q94601311 | Hygrophorus eburneus, edible mushroom, a promising natural bioactive agent |
| Q64076700 | Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogens and Its Receptors Into Cancer Physiopathology |
| Q94481955 | Inhibition of PI3K/AKT molecular pathway mediated by membrane estrogen receptor GPER accounts for cryptotanshinone induced antiproliferative effect on breast cancer SKBR-3 cells |
| Q92627789 | KDM2A-dependent reduction of rRNA transcription on glucose starvation requires HP1 in cells, including triple-negative breast cancer cells |
| Q92824703 | Malignant Pleural Effusion and Its Current Management: A Review |
| Q91781644 | Monitoring the Early Antiproliferative Effect of the Analgesic-Antitumor Peptide, BmK AGAP on Breast Cancer Using Intravoxel Incoherent Motion With a Reduced Distribution of Four b-Values |
| Q60921712 | PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer |
| Q92866391 | Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan |
| Q98159106 | RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC |
| Q64055629 | Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms |
| Q89637117 | SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells |
| Q64071099 | Steroid Receptor Signallings as Targets for Resveratrol Actions in Breast and Prostate Cancer |
| Q64097343 | The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway |
| Q92134544 | The Role of Exosomal microRNA in Cancer Drug Resistance |
| Q92181246 | The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases |
| Q90297667 | The biogenesis and biological functions of circular RNAs and their molecular diagnostic values in cancers |
| Q90479771 | Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer |
Search more.